ArticleCureus2026
Comparative Efficacy of Pioglitazone, Saroglitazar, and Silymarin on Biochemical and Histopathological Hepatic Outcomes in a Wistar Rat Model of Non-alcoholic Fatty Liver Disease and Their Correlation With Insulin Sensitivity.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundNon-alcoholic fatty liver disease (NAFLD) is the most common chronic liver disorder worldwide and is strongly associated with metabolic syndrome. Comparative evaluation of commonly used pharmacological agents is limited. This study aimed to evaluate and compare the effects of pioglitazone (PPAR‑γ agonist), saroglitazar (dual PPAR‑α/γ agonist), and silymarin on biochemical, anthropometric, and histopathological outcomes in a high-fat diet (HFD) Wistar rat model of NAFLD, and to assess their impact on insulin sensitivity Material and methods: Thirty adult male Wistar rats were randomized into five groups (n=6 each): normal control (standard diet), NAFLD control (HFD), and three treatment groups receiving pioglitazone (10 mg/kg), saroglitazar (4 mg/kg), or silymarin (400 mg/kg) orally for 28 days after seven weeks of HFD administration. Outcomes assessed included body weight (BW) and liver weight (LW), serum lipid profile, alanine aminotransferase (ALT), fasting glucose, insulin, Homeostasis Model Assessment of Insulin Resistance (HOMA‑IR), and histopathological scoring (steatosis, inflammation, fibrosis).
resultsSaroglitazar consistently provided the greatest benefits, showing significant reduction in serum cholesterol, triglycerides (TG), low-density lipoprotein cholesterol (LDL‑c), very low-density lipoprotein cholesterol (VLDL‑c), ALT, and HOMA‑IR, with marked restoration of high-density lipoprotein cholesterol (HDL‑c) and improved histology. Pioglitazone was effective in improving insulin sensitivity and steatosis, while silymarin exhibited hepatoprotective effects but with relatively modest improvements. INTERPRETATION AND
conclusionsSaroglitazar demonstrated the most comprehensive protective effects against NAFLD progression, surpassing pioglitazone and silymarin in biochemical, histological, and insulin resistance parameters. Its dual PPAR‑α/γ activity may offer a more effective therapeutic approach, supporting further translational evaluation in NAFLD management.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.